Caitlin Langford
Senior Director, Product, Pharma Solutions Perspectum
Seminars
Tuesday 17th March 2026
Multi-Organ MRI Enables Smarter, Mechanism-Driven CKLM Trials
11:30 am
- Label expansion is accelerating across CV, CKD, HFpEF and MASH, and CKLM trials would benefit from measuring cross-organ response, not just weight or eGFR
- Ectopic fat imaging (renal, cardiac, pancreatic, hepatic) quantifies cardiometabolic risk and treatment response at the tissue level
- Multi-organ inflammation, fibrosis and perfusion biomarkers capture therapeutic benefit beyond fat loss, enabling earlier readouts and stronger regulatory narratives
